CoChat

A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia

Open access

Published version of a preprint

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Background: Sodium oligomannate (GV-971), a marine-derived oligosaccharide, is a novel agent that may improve cognition in AD patients. Methods: The 24-week multicenter, randomized, double-blind, placebo parallel controlled clinical trial was conducted in AD in China between 24 October 2011 and 10 July 2013. The study included a 4-week screening/washout period, followed by a 24-week treatment period. Patients were randomized in a 1:1:1 ratio to receive GV-971 900 mg, 600 mg, or placebo capsule in treatment period, respectively. The primary outcome was cognitive improvement as assessed by changes in Alzheimer’s Disease Assessment Scale-cognitive subscale 12-item (ADAS-cog12) scores from baseline to week 24. The secondary efficacy outcomes included CIBIC-Plus, ADCS-ADL, and NPI at 24 weeks after treatment compared with baseline. A subgroup study was assessment of the change in cerebral glucose metabolism by fluorodeoxyglucose positron emission tomography measurements. Results: Comparing with the placebo group ( n = 83, change − 1.45), the ADAS-cog12 score change in the GV-971 600-mg group ( n = 76) was − 1.39 ( p = 0.89) and the GV-971 900-mg group ( n = 83) was − 2.58 ( p = 0.30). The treatment responders according to CIBIC-Plus assessment were significantly higher in the GV-971 900-mg group than the placebo group (92.77% vs. 79.52%, p < 0.05). The GV-971 900-mg subgroup showed a lower decline of cerebral metabolic rate for glucose than the placebo subgroup at the left precuneus, right posterior cingulate, bilateral hippocampus, and bilateral inferior orbital frontal at uncorrected p = 0.05. The respective rates of treatment-related AEs were 5.9%, 14.3%, and 3.5%. Conclusions: GV-971 was safe and well tolerated. GV-971 900 mg was chosen for phase III clinical study. Trial registration: ClinicalTrials.gov, NCT01453569 . Registered on October 18, 2011.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-020-00678-3

Cites

Statistics

Figures

Fig. 1 Patient disposition
Fig. 1 Patient dispositionCC BY · PubMed Central
Fig. 2 Full analysis set of the primary efficacy outcome of ADAS-cog12 change scores from baseline to week 24 among the three groups. p values were derived upon comparison of changes from week 24 to baseline with the placebo group
Fig. 2 Full analysis set of the primary efficacy outcome of ADAS-cog12 change scores from baseline to week 24 among the three groups. p values were derived upon comparison of changes from week 24 to baseline with the placebo groupCC BY · PubMed Central
Fig. 3 Full analysis set of the secondary efficacy outcome of CIBIC-Plus change score from baseline to week 24 among groups
Fig. 3 Full analysis set of the secondary efficacy outcome of CIBIC-Plus change score from baseline to week 24 among groupsCC BY · PubMed Central
Fig. 4 18F-FDG-PET measured changes of cerebral glucose metabolism (baseline – follow-up) in several AD related brain regions, revealing an improvement or slower decline in the 900-mg group than in the placebo group. p values displayed in the graph are not corrected for multiple comparison, and none survived multiple comparison correction
Fig. 4 18F-FDG-PET measured changes of cerebral glucose metabolism (baseline – follow-up) in several AD related brain regions, revealing an improvement or slower decline in the 900-mg group than in the placebo group. p values displayed in the graph are not corrected for multiple comparison, and none survived multiple comparison correctionCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 37 · Cited by 103

Research works printed but not linked: 1

  1. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):322–33. · DOI · Paper page

Metadata

Authors
Wang, T., Kuang, W., Chen, W., Xu, W., Zhang, L., Li, Y., Li, H., Peng, Y., Chen, Y., Wang, B., Xiao, J., Li, H., Yan, C., Du, Y., Tang, M., He, Z., Chen, H., Li, W., Lin, H., Shi, S., Bi, J., Zhou, H., Cheng, Y., Gao, X., Guan, Y., Huang, Q., Chen, K., Xin, X., Ding, J., Geng, M., & Xiao, S.
Affiliations
  • Shanghai Jiao Tong University (CN)
  • West China Hospital of Sichuan University (CN)
  • Sir Run Run Shaw Hospital (CN)
  • Harbin Medical University (CN)
  • Chinese People's Liberation Army (CN)
  • Nanjing Brain Hospital (CN)
  • Sun Yat-sen University (CN)
  • Second Affiliated Hospital of Chongqing Medical University (CN)
  • Baotou Central Hospital (CN)
  • Zhongnan Hospital of Wuhan University (CN)
  • Shandong University (CN)
  • Shandong Provincial Hospital (CN)
  • Guangzhou Psychiatric Hospital (CN)
  • First Hospital of China Medical University (CN)
  • Beijing Hospital (CN)
  • Tang Du Hospital (CN)
  • Southwest Hospital (CN)
  • Second Hospital of Shandong University (CN)
  • Daping Hospital (CN)
  • Tianjin Medical University General Hospital (CN)
  • Hunan Provincial People's Hospital (CN)
  • Fudan University (CN)
  • Banner Alzheimer’s Institute (US)
  • Chinese Academy of Sciences (CN)
Corresponding author
  • Wang, Tao
  • Geng, Meiyu
  • Xiao, Shifu
Venue
Alzheimer's Research & Therapy
Published
2020-09-14
Volume
12
Issue
1
Pages
110-110
ISSN
1758-9193 (ISSN-L)
OpenAlex
W3085133919
Cited by
103
References
37
Citations by year
2026: 16 · 2025: 12 · 2024: 15 · 2023: 22 · 2022: 23 · 2021: 14 · 2020: 1
FWCI
8.99
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s Research & Therapy (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Major Scientific and Technological Special Project (2011ZX09101-003-01)
  • National High Technology Research and Development Program of China (2006AA090501)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, dementia, cognitive impairment, oligosaccharides, brain glucose metabolism, FDG-PET, precuneus, posterior cingulate cortex, hippocampus, treatment response, drug safety and tolerability, dose comparison, Chinese patients, CIBIC-Plus, NPI
MeSH terms
Alzheimer Disease, China, Cholinesterase Inhibitors, Double-Blind Method, Humans, Mannose, Oligosaccharides, Sodium, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia. https://app.cochat.ai/papers/10.1186/s13195-020-00678-3
The paper
Wang, T., Kuang, W., Chen, W., Xu, W., Zhang, L., Li, Y., Li, H., Peng, Y., Chen, Y., Wang, B., Xiao, J., Li, H., Yan, C., Du, Y., Tang, M., He, Z., Chen, H., Li, W., Lin, H., . . . Xiao, S. (2020). A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-020-00678-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.